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Clinical correlation between hypercoagulability and thrombo-embollc
phenomena. A study of the coagulolytic balance as well as platelet
aggregation was carried out in 64 nephrotic patients. The data were
correlated, in a prospective attempt, with the clinical demonstration of
thrombo-embolic events. Activating factors (factors I, Vilic, VIIIr:Ag)
were increased as well as certain clotting inhibitors, a-l-antitrypsin and
a-2-macroglobulin. There was a platelet hyperaggregability in 3 1.5% of
our patients. Thrombo-embolic complications occured in six subjects
(9%). The data of these six patients were compared with that of the
others patients; no significant correlation were found between clotting
abnormalities and thrombosis. Low level of AT111 (<0.8 U.Fr) and
severe hypoalbuminemia (<20 g/liter) were of no predictive value for
the occurrence of thrombo-embolic events.
The incidence of thrombo-embolic complications in patients
with nephrotic syndrome varies between 8% and 33% [1]. In our
experience, at the time of a retrospective study covering a ten
year period, we noted 267 patients with nephrotic syndrome.
The incidence of thrombo-embolic events in this series was 4%.
The occurrence of these complications could be favored by a
disequilibrium of the coagulo-lytic balance, which is character-
ized by an increase of activating proteins (factors I, V, VII) and
a decrease of certain clotting inhibitors (AT111) associated with
a platelet hyperaggregability. Data from the literature concern-
ing these abnormalities are fragmented, focusing either on the
activating system, or the inhibiting system, or upon platelet
aggregation.
This led us to carry out a prospective study of the clotting
activators and inhibitors of the coagulolytic system as well as an
evaluation of platelet aggregation in 64 nephrotic patients. The
main aims of the study were: a) to establish an overall profile of
coagulation and platelet abnormalities and their relationship to
hypoalbuminemia, proteinuria and blood cholesterol; b) to
compare the level of coagulation of nephrotic patients having
thrombo-embolic complications with nephrotic patients free
from thrombotic complications; and c) to evaluate the relation-
ship between the clinical profile of these 64 patients (such as
presence or absence of thrombotic complications) and their
coagulation blood abnormalities.
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Methods
The 64 patients selected for the study had a serum albumin
less than 30 g/liter and protein excretion was greater than 3 g/24
hours. The mean age was 47 19 years and there were 32
females (mean age 45 20 years) and 32 males (mean age 48
18 years).
The nephrotic syndrome was primary in 36 patients and
secondary in 28 patients. Eighteen patients had nephrotic
syndrome without any other renal manifestations, while the
remaining 46 patients had hematuria and/or hypertension and/or
renal failure. Thrombo-embolic complications were observed in
six patients.
In order to correlate the relationship between the clinical
profile and coagulation abnormalities, the patients were distrib-
uted into two groups: group I were nephrotic patients with
thrombo-embolic complications (N = 6); and group II com-
prised nephrotic patients without thrombo-embolic complica-
tions (N = 58). To obtain additional correlations, we stratified
the 64 patients according to the level of AT111 and the serum
level of albumin. Patients with a low level of AT111 (< 0.8 U.Fr)
and patients with severe hypoalbuminemia (<20 g/liter) were
biologically considered at high thrombogenic risk; they were
respectively compared with patients having normal level of
AT111 and patients having hypoalbuminemia >20 g/liter. The
frequency of thrombo-embolic events was assessed in each
group in order to correlate biological data with thrombotic
complications. Finally the patients were subdivided into two
groups according to the presence or absence of a membranous
nephropathy. Laboratory data and evidence of thrombo-embol-
Ic events were also compared.
A transcutaneous renal biopsy was performed in 61 patients.
No drug had been previously administered. Blood samples were
taken in the morning in fasting patients without prolonged
venostasis. Platelet—count was performed by a Coulter Counter
(S + 2) (N = 250,000 50,000) (Coulter Electronics, Hialeah,
Florida, USA); platelet aggregability was evaluated according
to the Born, Cross method [2]; fibrinogen assay was done by the
technique of Von Clauss [3] (N = 300 50 mg/dl); the
prothrombin time was measured using Stago calcic anti-heparin
thromboplastin (N = I 0.2 U.Fr). Factor VIII coagulant was
determined according to the technique of Diagnostica Stago (N
= I 0.2 U.Fr); factor VIII antigenic (VIIIr:Ag) was measured
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Table 1 . Distribution of histological lesions (61 patients)
Histology Mi ch. Memb. Amyl. Foc. scler ANS Preecl. Mesang. prolif. Memb. Diabete K.W. Acute ON
Numberof cases II 9 8 6 6 5 5 4 4 3
Abbreviations are: Mi ch. (minimal change); Memb. (membranous); Amyl. (amyloidosis); Foc. scler. (focal sclerosis); ANS (arterio-nephro-
sclerosis); Preeci. (pre-eclampsia); Mesang. (mesangial); Memb. prolif. (membrano-proliferative); K.W. (Kimmelstiel-Wilson); Acute ON (acute
glomerulonephritis).
Table 2. Coagulation parameters for all 64 patients, Mean SD
VilIc VIllr:Ag P.T. Fib. C3
mg/dl
Plat.
giga/liter
Pig a-2AP
U.Fr.
a-2MA a-IAT CII
AT111
U.Fr.
Chol.
mmo!/litermg/dlUnit U.Fr.
Normal value 1 1 1 300 170 250 1 I
±0.2
200 1 5.2
Patients mean SD l.35c 2.75c 0.98 680C l2IC 342b I 0.98 366C 2l8 22 0.95 7•5C
Abbreviations are: factor VIII coagulant (VIlic); factor VIII related antigen (VIlIr:Ag); prothrombin time (P.T.); plasminogen (Pig); a-2-
antipiasmin (a-2AP); antithrombin III (AT111); unit fraction (U.Fr); librinogen (Fib.); third component of complement (C 3); a-2-macroglobulin (a-2-
MA); a-1-antitrypsin (a-I-AT); Cl inhibitor (CII); cholesterol (chol.)
P < 0.05
b P < 0.01
P < 0.001
by a laser nephelometry (N = I 0.2 U.Fr) [4]; assay of
fraction 3 of the complement was made by radial immunodiffu-
sion (N 170 70 mg/dl) (Partigen—Behring); the Kabi-Vitrum
chromogenic technique was used for the dosage of a-
2-antiplasmin (N = I 0.2 U.Fr); the Diagnostica Stago
chromogenic technique was used for the dosage of a-2-
macroglobulin (N = 200 100 mg/dl), a-l-antitrypsin (N = 190
60 mgldl), Cl inhibitor (N = 20 8 mg/dl); antithrombin III
(AT111) (N = I 0.2 U.Fr) and of plasminogen (N = 1 0.2
U .Fr).
Statistical analysis of the results are comprised of compari-
Sons of the averages of the results according to Student's t-test,
and correlation tests following a linear regression, as well as
test with YATES correction.
Results
Histological lesions are detailed in Table 1. The clotting
profile of 64 patients is represented in Table 2. Most of the
activating clotting factors were significantly increased when
compared to normal: fibrinogen (680 260 mgldl); factor VIIIC
(1.35 0.38 U.Fr), and factor VIIIr:Ag (2.75 1.38 U.Fr).
Fraction 3 of the complement was significantly decreased to 121
49 mgldl). For clotting inhibitors, we noted an increase of
a-2-macroglobulin to 366 166 mg/dl and of a-1-antitrypsin to
218 93 mg/dl, while Cl inhibitors a-2-antiplasmin and AT111
remain within the normal range.
There was a significant increase in the number of platelets to
342,000 144,000. The study of their aggregability performed
in 51 patients revealed 31.5% of hyperaggregability, 31.5% of
hypoaggregability and 37% of normal aggregation. As shown in
Table 3 there was a platelet hypersensitivity to low doses of
ADP (0.5 y) while their reactivity is normal with larger doses of
Table 3. Platelet aggregability to various doses of ADP and to
collagen
ADP
Collagen
Platelet
count0.5 y 1.25 y 2.5 y
Normal 15.1%
0.59%
38.9%
1.03%
52.5%
0.49%
54.31%
0.67%
250000
50000
Patients 30.8%
4.l%a
38.8%
3.7%
46.6%
3.92%
49.34%
2.6%
342 000
142000b
P < 0.001
b P < 0.01
ADP (1.25 and 2.5 y). The platelet response to collagen was
normal.
Comparison of the results according to the existence or the
absence of a thrombo-embolic complication
The group of six patients who presented a thrombo-embolic
complication (group I) was compared to the group of 58 patients
free from complication (group II). The only significant differ-
ence (Table 4) concerns Cli which was increased to 31.6 mgldl
in group I, while it was 21.6 mg/dl in group II. The magnitude of
the hypoalbuminemia and proteinuria did not differ significantly
in the two groups; the mean albuminemia was 18.8 4.7 g/l and
the mean proteinuria was 11.2 5 g!24 hours in group I,
whereas the mean values were 21.2 5.1 glliter and 8.8 6 g124
hours, respectively, in group II. The clinical and clotting
profiles of the six thrombotic patients are described in detail in
Tables 5 and 6. We noted a predominance of membranous
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Table 4. Coagulation parameters: patients with thrombo-embolic events (group I N = 6) versus patients without thrombo-embolic events (group
11 N = 58), mean SD
VilIc VlHr:Ag P.T. Fib. C3 PIg a-2AP -2MA a-IAT Cl!Plat. AT111 Chol.
Unit U.Fr. mg/dl giga/liter U.Fr. mg/dI U.Fr. mmollliter
Group 1 1.21 2.35 0.98 533 106 316 0.92 0.88 369 220 31 0.86 6.39
±0.4 ±1.54 ±0.23 ±176 ±64 ±63 ±0.28 ±0.16 ±221 ±69 ±13 ±0.21 ±3.03
Group II 1.35 2.75 0.99 670 123 369 1.02 0.98 366 218 21 0.95 7.46
±0.4 ±1.4 ±0.21 ±260 ±48 ±160 ±0.25 ±0.24 ±160 ±94 ±7 ±0.27 ±1.08
a p < 0.01
Table 5. Clinical and clotting profile of the six thrombotic patients
Prot Plat.
Case Histology S.Alb. U/day Thrombosis VIIlc VHIr:Ag Fib. Plat. PIg. a-2AP a-2MA a-IAT CII AT111 Aggr
I Nephro-scle- 19.7 3 bilateral 1.16 2.85 474 225 0.77 .7 214 238 49 0.9 Not done
rosis popliteal
thrombo-
sis
2 Membrano- 20 3.2 left iliofem- 1.2 1.97 570 421 1.2 1.12 234 155 38 1 Hyper
proliferative oral
3 Membranous 19 24 left renal 1.2 0.9 474 370 1.25 0.75 476 260 34 0.99 Hyper
vein
4 Membranous 12 6 Right and 1.3 4.6 1002 290 .68 0.90 213 305 12 0.9 Not done
left renal
veins
5 Mesangial 11 20 left arterial 1.2 0.95 810 435 .72 0.92 712 142 25 0.42 Hyper
embolism
6 Membranous 14 3.5 Right pop1i- 2.12 2.9 840 350 .95 0.25 382 252 50 0.8 Normal
teal
Table 6. Predisposing factors and evolution of the six thrombotic patients
Evolution of
Case Predisposing factor Delay thrombosis Evolution of nephro. synd. Histology
I Cardiac failure, long term 30 days favorable C.R.F. hemodialysis in 7 months nephrosclerosis
diuretic therapy (30
days)
2 Long term diuretic thera- 30 days favorable C.R.F. hemodialysis in 16 months membranous proliferation
py (30 days)
3 Membranous nephrop- Discovered during the favorable Disappearance by steroid therapy. membranous
athy first hospitalization Mild proteinuria (0.3 g124 hrs) 2
years after the onset of the dis-
ease
4 Long term diuretic thera- 60 days favorable Spontaneous regression persistent membranous
py (60 days). Membra- proteinuria (lg/24 hrs) 4 years
nous nephropathy after the onset of the disease
5 Long term diuretic thera- 90 days Amputation of the Patients died after surgery mesangial G.N.
py (60 days). Diar- left leg
rhoea, extracellular de-
hydration
6 Membranous nephrop- 15 months favorable Nephro, synd. persistent until the membranous
athy thrombotic complication, then
regression, persistent mild pro-
teinuria (0.40g124 hrs)
nephropathy (3 patients). Platelet hyperaggregability was noted The comparison of coagulation parameters of patients having
in three out of the four cases explored. hypoalbuminemia <20 g/liter with those of patients having
hypoalbuminemia >20 glliter (Table 7) revealed a significant
Thrombogenic risk, albuminemia and AT111 difference for fibrinogen, a-2-macroglobulin and cholesterol
which were inversely correlated with the severity of hypoalbu-
The thrombogenic risk factors during nephrotic syndrome, minemia. Platelet aggregation was increased in 38% of the
such as hypoalbuminemia <20 glliter and decreased level of patients with hypoalbuminemia <20 glliter, whereas it was
AT111 (<0.8 U.Fr), [5—7] were evaluated, increased in only 15% of patients with hypoalbuminemia >20
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Table 7. Coagulation parameters: patients with hypoalbuminemia < 20 g/liter (N = 29) versus patients with hypoalbuminemia > 20 glliter(N = 35), mean SD
VIHc VHIr:Ag P.T. Fib. C3
mg/dl
Plat.
giga/liter
Pig a-2AP
U.Fr.
a-2MA a-IAT Cii
AT111
U.Fr.
Chol.
mmol/litermg/dlUnit U.Fr.
ALB < 20 g/liter 1.37 2.39 0.99 842
274b
120 368 0.95 0.99 425 207 22 0.88 8.87
÷308b
ALB > 20 g/Iiter 1.36 2.99 0.98 559 115 316 1.04 0.99 316 232 21 I 6.48
a < 0.05
b < 0.01
Table 8. Coagulation parameters: patients with low AT111 Icvets (N = ii) versus patients with normal AT111 (N = 53), mean SD
Vilic VlLLr:Ag P.T. Fib. C3
mg/dl
Piat.
giga/liter
PIg a-2AP
U.Fr.
a-2MA a-IAT CII
AT111
U.Fr.
Chol.
mmol/!itermg/dlUnit U.Fr.
AT,11 1.19 2.49 0.98 713 110 400 0.73 0.83 381 183 20.3 0.63 9.31
<0.8 ±0.22 ±1.34 ±0.19 ±252 ±69 ±249 ±0.15" ±0.24a ±186 ±62 ±5.2 ±0.12" ±4.19a
AT111 1.36 2.8 I 670 123 335 1.06 1 365 227 22.5 1.02 7.25
>0.8 ±0.39 ±1.4 ±0.2 ±270 ±50 ±114 ±0.23 ±0.24 ±156 ±99 ±8.3 ±.24 ±2.37
a P < 0.05
b P < 0.001
Table 9. Coagulation parameters: patients with membranous nephropathy (N = 9) versus patients without membranous nephropathy (N = 55),
mean ± SD
Vilic VIIIr:Ag P.T. Fib. C3
mg/dl
Plat.
giga/liter
Pig s-2AP
U.Fr.
a-2MA a-1AT CII
AT111
U.Fr.
Chol.mmol/liter UnitU.Fr. mg/dl
Memb. n. 1.39 2.06 0.99 707 141 294 1.02 0.86 369 205 28 1.02 8.62
±0.37 ±1.06 ±0.18 ±179 ±45 ±118 ±0.22 ±0.32 ±109 ±74 ±lOa ±0.22 ±2.76
Others 1.35 2.75 0,98 680 119 352 1 0.99 368 223 21 0.94 7.28
±0.38 ± 1.38 ±0.12 ±280 ±45 ±149 ±0.26 ±0.21 ±170 ±98 ±0.25 ±2.36
a < 0.05
g/liter. However, the incidence of thrombo-embolic complica-
tions was the same in both groups.
When coagulation parameters of patients with low AT111 level
(<0.8 U.Fr) were compared with those of patients with normal
AT111 level, significant decrease of plasminogen and a-2-anti-
plasmin was noted in the former group (Table 8). Patients with
low AT111 level had more severe hypoalbuminemia (17 ± 4
g!liter versus 22 ± g/liter, P < 0.05) and greater proteinuria (12
± 6.7 g124 hrs versus 6.9 ± 5 g124 hrs, NS) than patients with
normal AT111 level. Platelet hyperaggregability and the inci-
dence of thrombo-embolic events were similar in both groups.
Thrombogenic risk and membranous nephropathy
When a comparison was made between nephrotic syndrome
secondary to membranous nephropathy and nephrotic syn-
drome due to other histological lesions, the only difference
concerns Cl! (Table 9). Platelet hyperaggregability was noted in
55% of patients with membranous nephropathy and in 20% of
patients with other histological lesions. Despite the absence of
difference in coagulation data between both groups (platelet
aggregability excepted) there was a large predominance of
thrombotic complications in patients with membranous nephrop-
athy (3 3%). The incidence of such complications was only 6% in
patients with other glomerulopathy.
Longitudinal study
The mean duration of the following up of the patients was
21.2 ± 14 months with extreme ranges from ito 48 months. Six
patients died: two were diabetics, two were afflicted by amy-
loidosis, one had membranous nephropathy, and one mem-
brano-proliferative glomerulonephritis. Out of these six pa-
tients, one presented a thrombo-embolic complication (case 5,
Table 5), and he died in the immediate post-embolic period.
Five of the coagulation complications observed, occurred
early with respect to the apparent onset of the nephrotic
syndrome (between 15 and 90 days, Table 6). Samples for the
coagulation study were collected just before the occurrence of
thrombosis. In one case (case 6 in Table 6) thrombosis appeared
after an evolution of 15 months. The results of the coagulation
study during the first hospitalization and at the time of the
thrombotic event are given in Table 10,
No significant modification was observed, and in particular
AT111 was normal at the time of the thrombotic event. Severe
hypoalbuminemia was persistent. In the other patients, no
thrombotic complication was observed and the successive
coagulation studies realised in the course of the nephrotic
syndrome remained unchanged. We noted a rapid normaliza-
tion of the disorders when the nephrotic syndrome disappeared.
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Table 10. Coagulation data during the first hospitalization and at the
time of the thrombotic complication
December
1981
March
1983
Aib. S 14 glliter 17 g/liter
Fib. 770 mg/dl 710 mg/dl
VIJIc 2.12 U.Fr 1.9 U.Fr
VIIIr:Ag 2.9 U.Fr 4 U.Fr
a-2-MA 309 mgldl 267 mgldl
a-2-AP 0.60 U.Fr 0.95 U.Fr
a-I-AT 185 mgldl 169 mgldl
Pig 0.9 U,Fr 1 U.Fr
Cli 24 mg/dl 18 mg/dl
AT111 0.8 U.Fr 0.93 U.Fr
Platelet
Aggregation Hyper Not done
Discussion
The increase of the specific proteins [8, 9] of the intrinsic
system, such as fibrinogen, prothrombin and factor VIII com-
plex, observed in the present study is in agreement with
previous observations [9, 101. In this study the mean plasma
fibrinogen level was more than twice the normal value. There
was a significant inverse relation between fibrinogen and
albuminemia (P < 0.001) and a significant correlation between
fibrinogen and blood cholesterol level (P < 0.001). High level of
plasma fibrinogen increases blood viscosity and it is an impor-
tant factor in the prethrombotic state of the nephrotic syn-
drome. Nevertheless, in our study fibrinogen level was of no
value for the prediction of a thrombo-embolic complication
(Table 4).
Urinary losses of factors Vilic and VIIIr:Ag do not occur
because of their high molecular weight. The increase of factor
VIIIr:Ag was more significant than that of factor VIlIc. In
contrast to some authors LI 1], we observed no correlations
between factor Vilic and VIIIr:Ag. These two proteins were of
no predictive value for the occurrence of thrombo-embolic
complications (Table 4). Their plasma levels were higher in
patients without thrombotic complications than in patients with
such complications.
A disequilibrium between the clotting activator system and
the inhibitor system may be important in the hypercoagulability
of nephrotic syndrome. Thus, urinary losses of small molecular
weight inhibitors, AT111 and a-I-AT have been observed [12,
13]. In the 64 patients of the present study, we noted an inverse
correlation between proteinuria and AT111 (P < 0.05) and
between proteinuria and a-I-AT (P < 0.05). There was a
positive correlation between the levels of serum albumin and
AT111 (P < 0.01). This is concordant with previous observations
relating a decrease of AT111 to serum albumin levels [8].
However, among the eleven patients with low AT111 levels
(<0.8), only one thrombotic episode was observed. Thus in the
present study the decrease of AT111 was not a good index of the
risk of thrombosis, This is in agreement with the studies of
Wagonner et al [14] whose patients with renal vein thrombosis
have been found to have normal levels of AT111.
A defect of fibrinolysis may also be important in the
hypercoagulability and the occurrence of thrombosis in the
nephrotic syndrome. In this study plasminogen levels were
normal in all 64 patients. However in patients with low AT111
levels (Table 8), plasminogen levels were significantly reduced
and there was a positive correlation between AT111 and
plasminogen (P < 0.01). Despite the important abnormalities of
the activator—inhibitor system observed in these eleven pa-
tients, the incidence of the coagulation complications was not
different from that observed in the other patients. Moreover,
mean plasminogen and AT111 levels are within the normal range
in the six thrombotic patients (Table 4).
Platelet hyperaggregability may also be considered as a
thrombogenic risk factor. We observed platelet hyperaggreg-
ability in 16 patients, and in seven of them spontaneous
aggregation occurred. Evaluation of platelet aggregation in-
duced by collagen and ADP demonstrated a normal platelet
response to collagen while it was increased by low doses of
ADP (0.5 y) and returned to normal with larger doses (1.25 y
and 2.5 y). This hypersensitivity of platelets to low doses of
ADP has been previously reported [8, 15]. Two proposed
mechanisms may be responsible for this response: hypercho-
lesterolemia and hypoalbuminemia [8, 16—18]. In this study the
patients with hyperaggregability had a lower serum albumin and
a higher serum cholesterol than the patients with a normal
platelet aggregability, but the differences were not significant.
The incidence of thrombotic complications is 18.75% (three of
16) in patients with hyperaggregability, versus 8.5% (three of
35) in patients with normo- or hypoaggregability. These per-
centages are not significantly different ( test with Yates
correction).
Five patients had three cumulative risk factors: hypoalbumin-
ia <20 g/liter, AT111 < 0.8 U.Fr, platelet hyperaggregability;
none of them presented a thrombo-embolic event during the
follow—up of this study.
Finally, clotting activators and inhibitors do not seem to be of
predictive value for thrombogenic risk. Considering our results,
the most important predictive factor is the existence of a
membranous nephropathy as 33% of the patients having this
histological lesion presented a thrombo-embolic complication,
and among the patients with thrombosis, 50% had membranous
nephropathy (Table 5). When we compare the clotting data of
thrombotic patients with that of non-thrombotic patients, no
significant difference emerges, save for C11 whose role as
inhibiting factor is minor. Thus it seems to us that nephrotic
syndrome may be considered generally as a hypercoagulable
state in which thrombotic events are started by additional
clinical events or therapy. We looked for the clinical manifes-
tations or therapy which could have increased blood viscosity
in our patients. We noted that four out of the six thrombotic
subjects had long—term diuretic therapy (Table 6), one of them
having an additional clinical factor of dehydration (case 5).
None of the non-thrombotic patients received long—term di-
uretic therapy. Thus, we believe that the induction of hypovo-
lemia in nephrotic syndrome may increase the blood hypervis-
cosity and add to the risk of thrombosis.
A prospective study may be necessary to assess the role of
long—term diuretic therapy in nephrotic patients.
In conclusion, it seems important to emphasize the incidence
of thrombo-embolic events (9%) in our series of 64 patients and
to underline the absence of parallelism between thrombo-
embolic complications and specific clotting abnormalities.
Thus, no clotting criterium is predictable for the occurrence of
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thrombo-embolic complications. The evidence of blood hyper-
viscosity in nephrotic syndrome is convincing. Circulating
conditions may play a preponderant role in the modifications of
blood coagulation.
Efforts should be made to develop therapeutic measures to
prevent hemodynamic abnormalities (diuretic therapy probably
represents an enhanced risk factor in these patients) and to
combat blood hyperviscosity. Membranous nephropathy is
associated with a high incidence of thrombotic complications,
but no biological factor is able to predict the onset of thrombo-
sis.
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